Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
about
Medical treatment for gastro-entero-pancreatic neuroendocrine tumoursOvarian cancer standard of care: are there real alternatives?(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United KingdomPazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.Antiangiogenic therapy for breast cancerFatigue in renal cell carcinoma: the hidden burden of current targeted therapiesA phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.Targeted therapies for non-small cell lung cancer: an evolving landscape.Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study groupConcise drug review: pazopanib and axitinib.A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.Targeting signaling pathways in ovarian cancer.Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinomaSystemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?Pazopanib: an antiangiogenic drug in perspective.Biology and management of inflammatory breast cancer.Past, present and future of therapies in pediatric sarcomas.In pursuit of new anti-angiogenic therapies for cancer treatmentOptimizing treatment for metastatic renal cell carcinoma.Emerging drugs for cervical cancer.Second-line systemic therapy for the treatment of metastatic renal cell cancer.Clinical trials and future potential of targeted therapy for ovarian cancer.An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.Emerging drugs for the treatment of cervical cancer.Renal effects of targeted anticancer therapies.Angiogenesis in cancer: Anti-VEGF escape mechanismsTargeting the VEGF pathway in metastatic bladder cancer.Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery?An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.Clinical management of metastatic kidney cancer: the role of new molecular drugs.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.Drug Repurposing to treat Asthma and Allergic Disorders: Progress and Prospects.Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.
P2860
Q26751659-FD40AA3C-085F-405F-A600-134C0B74EC34Q26862249-EC987B27-EB79-4B2B-9258-0D3C3515C220Q33590458-32F78673-F65E-4F46-9B2C-970A866565FEQ33786788-3D05F7E8-AF70-4E42-9156-8761004C5BA5Q33821666-03556186-355D-426C-9A97-CB5CDB4383BDQ33834417-3B3C4218-7DDA-47ED-9B33-F58218809C23Q34989039-1CF56903-5241-4934-A2A2-7032F46D45E4Q35583812-744462A3-B4DA-4F13-9142-0F943C833E0CQ35584239-604E0145-0BFA-4CCB-AE60-9632E48853D8Q35628597-F92AEBB1-91FE-4A43-9189-F0A362E3E8F8Q35879884-35DF6B9C-F1C9-4284-ABA6-C1C62D5AB241Q36182836-74BAF08B-0084-453B-ABD0-0D8645289007Q36514752-7D13BAD8-50D1-40CB-8B17-CF90812EBBC5Q36842503-EAB1275C-8C68-48B5-AEED-E083A6274608Q37071204-64AD43B9-2627-4FA6-A2DA-964C9E1FA234Q37082789-BE8A4ED9-7D46-4228-B39A-FF55CB31AB1AQ37111609-462BA625-2D56-474C-BC2A-A0E10EA5036CQ37575635-EE9DEBE5-FF7D-4883-A2DE-A056A62922BEQ37630567-425F5697-71A6-45F1-B58F-796F128C364DQ37687382-8E9C2DB6-67BA-4BA0-9AAC-30FF98B7D793Q37725915-0BF44FF7-6D69-406A-ADFC-EE2BB3EC45BEQ37825180-70E8D123-AB29-4D0A-9C9E-93C4B219CCBCQ37960915-1DF9FE6D-B543-4F33-87E3-EF7C5B62A749Q38005222-B9887A02-8CAE-4AC8-8393-C57AE0CC279DQ38020244-5CDE0A2D-22CD-4B59-A8DF-9F4EDE6531DCQ38038489-D55D07DA-7B16-41B6-B827-11D31A31083FQ38077494-8335FD77-301D-4785-B545-F42DB587EC94Q38095989-12C8E7DF-FF96-42F5-9AE3-C462D001F902Q38115596-6C34D67B-844A-4658-9F52-F4BD9133909FQ38314157-585543DE-3EC8-44BF-9D75-8BDDA306FB6BQ38367168-14166507-D3F7-41B2-BFF4-55EE2A67E73EQ38389975-19CE7C7A-94C2-41CE-9DF2-FA0DF61E70A3Q38534167-DE0693D1-6860-431B-BA05-FFCC18E6A50EQ38598277-B28A2D31-B23A-42E9-8E9B-16903E463EE1Q38631373-F0B85C2C-4555-42B4-82E4-0F63FDCC01A6Q38652566-631A4D10-5807-40AF-8909-45629809E4D9Q38936104-CDD5C2FA-CAB8-41C4-BD59-36CCA22DB57FQ38985337-6CEEF144-F286-4BDE-AF45-CAF8D7BE09DAQ39150081-6BCF84C4-FC9B-4A43-B4A2-9160DEDE677EQ39755748-08A78BC7-E2EF-48DE-8781-77F38A877F6E
P2860
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
@ast
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
@en
type
label
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
@ast
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
@en
prefLabel
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
@ast
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
@en
P1476
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
@en
P2093
Guru Sonpavde
Thomas E Hutson
P2888
P304
P356
10.1007/S11912-007-0007-2
P577
2007-03-01T00:00:00Z